View Item 

Show simple item record

Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity
dc.contributor.authorPagano, Monica B.
dc.contributor.authorHarmon, Charles
dc.contributor.authorCooling, Laura
dc.contributor.authorConnelly‐smith, Laura
dc.contributor.authorMann, Steven A.
dc.contributor.authorPham, Huy P.
dc.contributor.authorMarques, Marisa B.
dc.contributor.authorSchlueter, Annette J.
dc.contributor.authorCase, Rosemary
dc.contributor.authorKing, Karen E.
dc.contributor.authorCataife, Guido
dc.contributor.authorWu, Yanyun
dc.contributor.authorWong, Edward C. C.
dc.contributor.authorWinters, Jeffrey L.
dc.date.accessioned2016-11-18T21:22:50Z
dc.date.available2018-01-08T19:47:52Zen
dc.date.issued2016-11
dc.identifier.citationPagano, Monica B.; Harmon, Charles; Cooling, Laura; Connelly‐smith, Laura ; Mann, Steven A.; Pham, Huy P.; Marques, Marisa B.; Schlueter, Annette J.; Case, Rosemary; King, Karen E.; Cataife, Guido; Wu, Yanyun; Wong, Edward C. C.; Winters, Jeffrey L. (2016). "Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity." Transfusion 56(11): 2848-2856.
dc.identifier.issn0041-1132
dc.identifier.issn1537-2995
dc.identifier.urihttps://hdl.handle.net/2027.42/134412
dc.publisherCambridge University Press
dc.publisherWiley Periodicals, Inc.
dc.titleUse of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134412/1/trf13795.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134412/2/trf13795_am.pdf
dc.identifier.doi10.1111/trf.13795
dc.identifier.sourceTransfusion
dc.identifier.citedreferenceCanet E, Zafrani L, Lambert J, et al. Acute kidney injury in patients with newly diagnosed highâ grade hematological malignancies: impact on remission and survival. PLoS One 2013; 8: e55870.
dc.identifier.citedreferenceNiemi TT, Kuitunen AH. Hydroxyethyl starch impairs in vitro coagulation. Acta Anaesthesiol Scand 1998; 42: 1104.
dc.identifier.citedreferenceGattas DJ, Dan A, Myburgh J, et al. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013; 39: 558 â 68.
dc.identifier.citedreferencePatel A, Waheed U, Brett SJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and metaâ analysis. Intensive Care Med 2013; 39: 811 â 22.
dc.identifier.citedreferenceFDA Safety Communication: Boxed warning on increased mortality and severe renal injury, and additional warning on risk of bleeding, for use of hydroxyethyl starch solutions in some settings [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2013 [cited 2016 Jan]. Available from: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm358271.htm.
dc.identifier.citedreferenceHydroxyethylâ starch solutions (HES) no longer to be used in patients with sepsis or burn injuries or in critically ill patients: HES will be available in restricted patient populations [Internet]. London: Pharmacovigilance Risk Assessment Committee of the European Medicines Agency; 2013 Dec 19 [cited 2016 Jan]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Solutions_for_infusion_containing_hydroxyethyl_starch/European_Commission_final_decision/WC500162361.pdf.
dc.identifier.citedreferenceUS Food and Drug Administration adds black boxed warning to hydroxyethyl starch (HES) [Internet]. Vancouver (BC): American Society for Apheresis; 2013 Sep 12 [cited 2016 Jan]. Available from: https://asfamalachite-mgmt.site-ym.com/news/269049/US-Food-and-Drug-Administration-adds-black-boxed-warning-to-Hydroxyethyl-starch-HES.htm.
dc.identifier.citedreferenceNovotny JR, Müllerâ Beissenhirtz H, Hergetâ Rosenthal S, et al. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. Eur J Haematol 2005; 74: 501 â 10.
dc.identifier.citedreferenceHester JP, Kellogg RM, Freireich EJ. Mononuclear cell (MNC) collection by continuousâ flow centrifugation (CFC). J Clin Apher 1983; 1: 197 â 201.
dc.identifier.citedreferenceHarris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)â a metadataâ driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377 â 81.
dc.identifier.citedreferenceCameron A, Trivedi P. Microeconometrics. Methods and applications. New York: Cambridge University Press; 2005.
dc.identifier.citedreferenceJena AB, Goldman DP, Seabury SA. Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females. JAMA Intern Med 2015; 175: 617 â 23.
dc.identifier.citedreferenceWestphal M, James MF, Kozekâ Langenecker S, et al. Hydroxyethyl starches: different productsâ different effects. Anesthesiology 2009; 111: 187 â 202.
dc.identifier.citedreferenceBrecher ME, Owen HG, Bandarenko N. Alternatives to albumin: starch replacement for plasma exchange. J Clin Apher 1997; 12: 146 â 53.
dc.identifier.citedreferenceLondon MJ, Ho JS, Triedman JK, et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 1989; 97: 785 â 97.
dc.identifier.citedreferenceDarmon M, Vincent F, Camous L, et al. Tumour lysis syndrome and acute kidney injury in highâ risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Oncoâ Hematologique. Br J Haematol 2013; 162: 489 â 97.
dc.identifier.citedreferenceIacone A, Di Bartolomeo P, Di Girolamo G, et al. Hydroxyethyl starch and steroid improved collection of normal granulocytes with continuous flow centrifugation gravity leukapheresis. Haematologica 1981; 66: 645 â 55.
dc.identifier.citedreferenceAmbruso DR. Hydroxyethyl starch and granulocyte transfusions: considerations of utility and toxicity profile for patients and donors. Transfusion 2015; 55: 911 â 8.
dc.identifier.citedreferenceArslan O, Arat M, Tek I, et al. Therapeutic plasma exchange in a single center: Ibni Sina experience. Transfus Apher Sci 2004; 30: 181 â 4.
dc.identifier.citedreferenceArslan O, Tek I, Arat M, et al. Effects of replacement fluids on plasma viscosity used for therapeutic plasma exchange. Ther Apher Dial 2004; 8: 144 â 7.
dc.identifier.citedreferenceCid J, Ortín X, Elies E, et al. Hydroxyethylstarch as a replacement fluid in therapeutic plasma exchange for lupus nephritis in a Jehovah’s Witness. Transfus Apher Sci 2003; 28: 101 â 2.
dc.identifier.citedreferenceLe Conte P, Nicolas F, Adjou C, et al. Replacement fluids in plasmapheresis: crossâ over comparative study. Intensive Care Med 1997; 23: 342 â 4.
dc.identifier.citedreferenceAuwerda JJ, Wilson JH, Sonneveld P. Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis. Ann Intern Med 2002; 137: 1013 â 4.
dc.identifier.citedreferenceAuwerda JJ, Leebeek FW, Wilson JH, et al. Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch. Transfusion 2006; 46: 1705 â 11.
dc.identifier.citedreferencePeron S, Mouthon L, Guettier C, et al. Hydroxyethyl starchâ induced renal insufficiency after plasma exchange in a patient with polymyositis and liver cirrhosis. Clin Nephrol 2001; 55: 408 â 11.
dc.identifier.citedreferenceRing J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1: 466 â 9.
dc.identifier.citedreferenceStrauss RG. Review of the effects of hydroxyethyl starch on the blood coagulation system. Transfusion 1981; 21: 299 â 302.
dc.identifier.citedreferencePorcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000; 39: 1 â 18.
dc.identifier.citedreferenceOberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and lowâ dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and metaâ analysis. Leuk Res 2014; 38: 460 â 8.
dc.identifier.citedreferenceSchwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practiceâ evidenceâ based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28: 145 â 284.
dc.identifier.citedreferenceSakr Y, Payen D, Reinhart K, et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007; 98: 216 â 24.
dc.identifier.citedreferenceRioux JP, Lessard M, De Bortoli B, et al. Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med 2009; 37: 1293 â 8.
dc.identifier.citedreferenceDart AB, Mutter TC, Ruth CA, et al. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010;( 1 ): CD007594.
dc.identifier.citedreferenceBrunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125 â 39.
dc.identifier.citedreferenceLissauer ME, Chi A, Kramer ME, et al. Association of 6% hetastarch resuscitation with adverse outcomes in critically ill trauma patients. Am J Surg 2011; 202: 53 â 8.
dc.identifier.citedreferenceMyburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901 â 11.
dc.identifier.citedreferenceGuidet B, Martinet O, Boulain T, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 2012; 16: R94.
dc.identifier.citedreferencePerner A, Haase N, Guttormsen AB. Hydroxyethyl starch 130/0.4 versus Ringer’s acetate in severe sepsis. N Engl Med 2012; 367: 124 â 34.
dc.identifier.citedreferenceBayer O, Reinhart K, Kohl M, et al. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis. A prospective sequential analysis. Crit Care Med 2012; 40: 2543 â 51.
dc.identifier.citedreferenceNavickis RJ, Haynes GR, Wilkes MM. Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a metaâ analysis of randomized trials. J Thorac Cardiovasc Surg 2012; 144: 223 â 30.
dc.identifier.citedreferenceHaase N, Perner A, Hennings LI, et al. Hydroxyethyl starch 130/0.38â 0.45 versus crystalloid or albumin in patients with sepsis: systematic review with metaâ analysis and trial sequential analysis. BMJ 2013; 346: f839.
dc.identifier.citedreferenceZarychanski R, Abouâ Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and metaâ analysis. JAMA 2013; 309: 678 â 88.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
trf13795.pdf
Size:
171.7KB
Format:
PDF
View/Open
Name:
trf13795_am.pdf
Size:
324.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.